NCT02228421View on ClinicalTrials.gov

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

TerminatedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Non-small Cell Lung Cancer Metastatic
Trial Locations (3)

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

J5L 5T1

CSSS de Rimouski-Neigette, Rimouski

Sponsors

Lead Sponsor

PeriPharm
All Listed Sponsors
collaborator

Personalized Medicine Partnership for Cancer

OTHER

collaborator

Jewish General Hospital

OTHER

lead

PeriPharm

OTHER

NCT02228421 - Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients | Biotech Hunter | Biotech Hunter